Home
L. Y. Dirix, D. Schrijvers, P. Druwé, J. Van den Brande, D. Verhoeven, A. T. Van Oosterom.
Pulmonary toxicity and bleomycin (letter). Lancet 1994, July 2, 344 (8914) : 56.

D. Schrijvers, A. M. Morel, J. Van den Brande, P. Vroman, L. Dirix, A. Prové, A. T. Van Oosterom.
Bloedingen en thrombo-embolische complicaties bij patiënten met vaste tumoren. Tijdschrift voor geneeskunde: 1998; 54(3): 171-8.

J. Van den Brande, D. Schrijvers, D. Becquart, A. Prové, L. Dirix, A. T. Van Oosterom.
Late relapse in nonseminomatous germ cell tumour from residual mature teratoma. Acta Clinica Belgica: 1998; 53(3): 193-7.

D. Schrijvers, J. Van den Brande, J. B. Vermorken.
Pulmonary embolism (letter). New England Journal of Medicine: 1998; 339(21): 1555.

J. Van den Brande, D. Schrijvers, C. Colpaert, J. B. Vermorken.
Cytomegalovirus colitis after administration of docetaxel/5-fluorouracil/cisplatin chemotherapy for locally advanced hypopharyngeal cancer. Ann Oncol 1999; 10(11):1369-72.

Y. Mentens, D. Schrijvers, J. Van den Brande, P. Van Schil, J. B. Vermorken.
Thoracic wall prosthesis prevents deep invasion by non-small-cell lung cancer. American Journal of Clinical Oncology 2000; 23(1):32-3.

J. Damen, D. Schrijvers, J. Van den Brande, J. Pelgrims, J. Vermorken.
Intraperitoneal treatment of peritoneo-venous shunt infection in a cancer patient. (letter) Scand J Infect Dis 2000; 32(1):106.

Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken JB.
Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000; 82(2):291-4.

Schrijvers D, Van den Brande J, Vermorken JB.
Supravenous discoloration of the skin due to docetaxel treatment. Br J Dermatol 2000; 142:1069-70.

Van den Brande J, Nannan Panday VR, Hoekman K, Rosing H, Huijskes RV, Verheijen RH, Beijnen JH, Vermorken JB.
Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors. Am J Clin Oncol 2001; 24(4):401-3.

J. Van den Brande, D. Schrijvers, P. Wilmes, J. B. Vermorken.
Practical implications of drug administrations. CME Journal of Gynecologic Oncology 2001; :43-51.

Schoffski P, Herr A, Vermorken JB, Van den Brande J, Beijnen JH, Rosing H, Volk J, Ganser A, Adank S, Botma HJ, Wanders J.
Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue. Eur J Cancer 2002;38(6):807-13.

van Outryve S, Schrijvers D, van den Brande J, Wilmes P,Bogers J, van Marck E, Vermorken JB.
Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review. Neth J Med 2002; 60(5):216-22.

Hendriks JM, van Putte B, Romijn S, van den Brande J, Vermorken JB, van Schil PE.
Pneumonectomy for lung metastases: report of ten cases. Thorac Cardiovasc Surg. 2003 Feb;51(1):38-41.

Van den Brande J, Schoffski P, Schellens JH, Roth AD, Duffaud F, Weigang-Kohler K, Reinke F, Wanders J, de Boer RF, Vermorken JB, Fumoleau P.
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer. 2003 Mar 10;88(5):648-53.